Jonathan Wolleben
Stock Analyst at JMP Securities
(3.79)
# 624
Out of 4,814 analysts
203
Total ratings
42.21%
Success rate
8.69%
Average return
Main Sectors:
Stocks Rated by Jonathan Wolleben
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MBX MBX Biosciences | Initiates: Market Outperform | $38 | $7.63 | +398.03% | 1 | Apr 10, 2025 | |
| ALT Altimmune | Reiterates: Market Outperform | $25 | $4.54 | +450.66% | 12 | Apr 2, 2025 | |
| CLSD Clearside Biomedical | Reiterates: Market Outperform | $5 | $0.86 | +483.98% | 10 | Mar 28, 2025 | |
| KALV KalVista Pharmaceuticals | Reiterates: Market Outperform | $19 | $12.09 | +57.15% | 3 | Mar 26, 2025 | |
| AURA Aura Biosciences | Maintains: Market Outperform | $21 → $19 | $5.37 | +253.82% | 7 | Mar 26, 2025 | |
| SKYE Skye Bioscience | Reiterates: Market Outperform | $15 | $1.44 | +945.30% | 2 | Mar 21, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Market Outperform | $61 | $46.32 | +31.69% | 11 | Mar 10, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Market Outperform | $22 → $19 | $7.34 | +158.86% | 17 | Mar 4, 2025 | |
| DBVT DBV Technologies | Reiterates: Market Outperform | $10 | $7.76 | +28.87% | 13 | Mar 4, 2025 | |
| PHVS Pharvaris | Reiterates: Market Outperform | $55 | $14.00 | +292.86% | 11 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $18 | $7.39 | +143.57% | 7 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $26 | $4.03 | +545.16% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $91 → $87 | $21.69 | +301.20% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $92 → $91 | $30.40 | +199.34% | 14 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $74 | $38.63 | +91.56% | 9 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $427 | $301.73 | +41.52% | 11 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $75 | $61.65 | +21.65% | 2 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $3.01 | +199.50% | 8 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $55 → $50 | $33.10 | +51.06% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $90 | $80.51 | +11.79% | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $112.70 | - | 1 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $1.15 | +598.69% | 7 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $3 | $0.12 | +2,339.02% | 7 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Accumulate | $420 → $485 | $574.48 | -15.58% | 1 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $3 | $0.33 | +819.40% | 6 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $48 → $32 | $2.21 | +1,347.96% | 8 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $25 | $1.90 | +1,215.79% | 11 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $8 | $0.25 | +3,062.06% | 11 | Apr 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $24 | $29.08 | -17.45% | 1 | May 12, 2023 |
MBX Biosciences
Apr 10, 2025
Initiates: Market Outperform
Price Target: $38
Current: $7.63
Upside: +398.03%
Altimmune
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $25
Current: $4.54
Upside: +450.66%
Clearside Biomedical
Mar 28, 2025
Reiterates: Market Outperform
Price Target: $5
Current: $0.86
Upside: +483.98%
KalVista Pharmaceuticals
Mar 26, 2025
Reiterates: Market Outperform
Price Target: $19
Current: $12.09
Upside: +57.15%
Aura Biosciences
Mar 26, 2025
Maintains: Market Outperform
Price Target: $21 → $19
Current: $5.37
Upside: +253.82%
Skye Bioscience
Mar 21, 2025
Reiterates: Market Outperform
Price Target: $15
Current: $1.44
Upside: +945.30%
Protagonist Therapeutics
Mar 10, 2025
Reiterates: Market Outperform
Price Target: $61
Current: $46.32
Upside: +31.69%
Ocular Therapeutix
Mar 4, 2025
Maintains: Market Outperform
Price Target: $22 → $19
Current: $7.34
Upside: +158.86%
DBV Technologies
Mar 4, 2025
Reiterates: Market Outperform
Price Target: $10
Current: $7.76
Upside: +28.87%
Pharvaris
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $55
Current: $14.00
Upside: +292.86%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $7.39
Upside: +143.57%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $26
Current: $4.03
Upside: +545.16%
Feb 28, 2025
Maintains: Market Outperform
Price Target: $91 → $87
Current: $21.69
Upside: +301.20%
Feb 28, 2025
Maintains: Market Outperform
Price Target: $92 → $91
Current: $30.40
Upside: +199.34%
Feb 24, 2025
Reiterates: Market Outperform
Price Target: $74
Current: $38.63
Upside: +91.56%
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $427
Current: $301.73
Upside: +41.52%
Dec 23, 2024
Reiterates: Market Outperform
Price Target: $75
Current: $61.65
Upside: +21.65%
Dec 19, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $3.01
Upside: +199.50%
Dec 18, 2024
Maintains: Market Outperform
Price Target: $55 → $50
Current: $33.10
Upside: +51.06%
Dec 16, 2024
Reiterates: Market Outperform
Price Target: $90
Current: $80.51
Upside: +11.79%
Dec 16, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $112.70
Upside: -
Dec 12, 2024
Reiterates: Market Outperform
Price Target: $8
Current: $1.15
Upside: +598.69%
Dec 11, 2024
Downgrades: Market Perform
Price Target: $3
Current: $0.12
Upside: +2,339.02%
Nov 13, 2024
Downgrades: Accumulate
Price Target: $420 → $485
Current: $574.48
Upside: -15.58%
Sep 26, 2024
Reiterates: Market Outperform
Price Target: $3
Current: $0.33
Upside: +819.40%
Aug 15, 2024
Maintains: Market Outperform
Price Target: $48 → $32
Current: $2.21
Upside: +1,347.96%
May 31, 2024
Reiterates: Market Outperform
Price Target: $25
Current: $1.90
Upside: +1,215.79%
Apr 19, 2024
Reiterates: Market Outperform
Price Target: $8
Current: $0.25
Upside: +3,062.06%
May 12, 2023
Maintains: Outperform
Price Target: $25 → $24
Current: $29.08
Upside: -17.45%